POZ - Treatment News : CD4s Predictive of Non-AIDS-Related Health Problems

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2008

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


email print

April 24, 2008

CD4s Predictive of Non-AIDS-Related Health Problems

Keeping CD4 counts above 350 significantly reduces the risk of developing both AIDS- and non-AIDS-related health problems, according to a study published in the April 23 issue of AIDS. This finding lends further credibility to recent changes to adult HIV treatment guidelines moving the threshold for when to start HIV treatment from 200 to 350 CD4 cells.

Experts have long argued that ARV therapy comes with benefits and risks. While it can dramatically reduce the risk of dying of an AIDS-related disease, the longer survival it affords likely increases the chances of an HIV-positive person facing a non-AIDS-related illness, including those associated with other infections (e.g., viral hepatitis) and risk factors (smoking). While studies have confirmed this, research has also shown that people not on ARV therapy face a higher risk of non-AIDS cardiovascular-, cancer- and kidney-related diseases than those who are on ARV treatment. 

Jason Baker, MD, from the University of Minnesota in Minneapolis, and his colleagues reckoned that just as higher CD4 counts while not on ARV treatment lowers the risk of AIDS-related health problems, a healthy immune response to HIV therapy is also protective against non-AIDS-related diseases.  To test this hypothesis, Baker’s team analyzed data from the FIRST study, which ran between 1999 and 2002, comparing three different treatment strategies in 1,397 people living with HIV new to ARV treatment. One group started a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination, a second group started a regimen including a protease inhibitor (PI), and a third group started a regimen containing both.

During the course of the study, 227 people developed an AIDS-related disease and 80 developed a non-AIDS-related disease, including cancers and cardiovascular, kidney and liver diseases. Baker’s team found that when people had a CD4 count below 200, despite being on treatment, their risk for developing an AIDS-related disease was nearly 14 times higher than in people with an on-treatment CD4 count above 350. Their risk of developing non-AIDS-related diseases was more than twice as high as in people with higher CD4s.

With an on-treatment CD4 count between 200 and 350, the risk of developing an AIDS-related illness was still higher than in those with counts on treatment above 350, but only twice as high, while the risk of a non-AIDS-related health problem remained twice that of those with CD4s above 350.

Baker’s group concludes by calling for studies investigating the benefit of starting ARV treatment at higher CD4 counts and for further studies examining the potential links between CD4s and non-AIDS-related diseases.

Search: CD4, Jason Baker, University of Minnesota, NNRTI, PI, cardiovascular, kidney, cancer, FIRST


Scroll down to comment on this story.

email print

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

  comments 1 - 4 (of 4 total)    

tamrat, Mekelle -ETHIOPIA, 2008-05-01 06:56:34
Ya cd4 count is low the patient faced to Opportunistic infections.I am in the 2nd line regiment for 4 years my cd4 count is still low . thanks Poz.

Eddie, Pittsburgh, 2008-04-30 12:45:06
Michael, ARV is....Anti Retro Viral Theropy

Moges, Addis Abeba Ethiopia, 2008-04-30 12:14:20
I am spoonsoring some HIV patiens to get spirulina as a suplimantry food. We support those who have started the durg and those who did not start the ART drug. Their CD 4 count increased by 100 % with in a moth time and alsomst all group are less afected by Opportunistic infection and when their CD four count increases they are not affected by other deseases

Michael, , 2008-04-25 22:10:51
What is ARV therapy?

comments 1 - 4 (of 4 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar
Starting Treatment
Quilt in the Capital
POZ Army


    Classylady30
    Charlotte
    North Carolina


    guycmh328
    Columbus
    Ohio


    tempeststar
    Midtown NYC
    New York


    ZanderPetros
    San Jose
    California
Click here to join POZ Personals!
Talk to Us
Poll
Do you support rapid in-home HIV testing?
Yes
No

Survey
Health 2.0

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.